Tech Company Financing Transactions
ImmunGene Funding Round
On 11/8/2013, ImmunGene received $9 million in Series A funding from Ally Bridge Group.
Transaction Overview
Company Name
Announced On
11/8/2013
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series A
Investors
Ally Bridge Group (Frank Yu)
Proceeds Purpose
ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
558 St. Charles Dr. 200
Thousand Oaks, CA 93012
USA
Thousand Oaks, CA 93012
USA
Phone
Website
Email Address
Overview
ImmunGene is a drug discovery and development company, developing monoclonal antibody-based therapeutics to treat cancer and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sanjay Khare
Chief Operating Officer
Raj Sachdev
Chief Scientific Officer
Michael Gresser
Chief Scientific Officer
Iqbal Grewal
VP - Bus. Development
Linda Pullan
Browse more venture capital transactions:
Prev: 11/8/2013: DNAtriX venture capital transaction
Next: 11/8/2013: Jut venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records on this site come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs